Sreekumar R found that ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in CRC (Sreekumar et al., 2021). The gene discussed is ERCC4; the disease is colorectal carcinoma.